Paul M. Mendelman

Paul M. Mendelman

No más puestos en curso

76 años
Health Technology
Consumer Services
Commercial Services

Perfil

Paul M.
Mendelman
worked as a Director of Clinical Research Infectious Diseases at Merck & Co., Inc. from 1991 to 1996.
He then worked as a Vice President of Clinical Development at MedImmune LLC from 2002 to 2005.
He also held the position of Vice President of Clinical Development at MedImmune Vaccines, Inc. and Senior Vice President of Clinical Development at Telik, Inc. He was the Chief Medical Officer & EVP at LigoCyte Pharmaceuticals, Inc. and later became the Chief Medical Officer at Aridis Pharmaceuticals, Inc. He returned to Aridis Pharmaceuticals, Inc. in 2019 as the Chief Medical Officer until 2020.
From 2012 to 2017, he worked as the Vice President of Medical at Takeda Vaccines, Inc. Dr. Mendelman received his undergraduate and doctorate degrees from The Ohio State University.

Antiguos cargos conocidos de Paul M. Mendelman.

EmpresasCargoFin
ARIDIS PHARMACEUTICALS, INC. Director Técnico/Científico/I+D 15/06/2020
Corporate Officer/Principal 01/01/2017
LigoCyte Pharmaceuticals, Inc. Director Técnico/Científico/I+D 16/04/2014
Corporate Officer/Principal 01/01/2005
MERCK & CO., INC. Corporate Officer/Principal 01/01/1996
Ver el detalle de la experiencia de Paul M. Mendelman.

Formación de Paul M. Mendelman.

The Ohio State University Doctorate Degree

Experiencias
Funciones ocupadas

Activas

Inactivas

Empresas cotizadas

Empresas privadas

Ver el detalle de la experiencia de Paul M. Mendelman.

Relaciones

100 +

Relaciones de 1er grado

8

Empresas vinculadas al 1er grado

Hombre

Mujer

Administradores

Ejecutivos

Consultar la red personal

Empresas relacionadas

Empresas cotizadas2
MERCK & CO., INC.

Health Technology

ARIDIS PHARMACEUTICALS, INC.

Health Technology

Empresas privadas5

Health Technology

Health Technology

Health Technology

LigoCyte Pharmaceuticals, Inc.

Health Technology

Commercial Services

Ver las conexiones de la empresa
  1. Bolsa de valores
  2. Insiders
  3. Paul M. Mendelman
-40% Prolongación excepcional: Nuestras suscripciones le guían hacia las mejores inversiones del mañana.
APROVÉCHELO AHORA